The WACC of Sarana Meditama Metropolitan Tbk PT (SAME.JK) is 10.4%.
Range | Selected | |
Cost of equity | 10.6% - 13.6% | 12.1% |
Tax rate | 41.2% - 45.0% | 43.1% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 9.2% - 11.6% | 10.4% |
Category | Low | High |
Long-term bond rate | 6.6% | 7.1% |
Equity market risk premium | 7.9% | 8.9% |
Adjusted beta | 0.51 | 0.67 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 10.6% | 13.6% |
Tax rate | 41.2% | 45.0% |
Debt/Equity ratio | 0.23 | 0.23 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 9.2% | 11.6% |
Selected WACC | 10.4% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
SAME.JK | Sarana Meditama Metropolitan Tbk PT | 0.23 | 0.7 | 0.62 |
40T.SI | ISEC Healthcare Ltd | 0.08 | -0.07 | -0.06 |
8769.T | Advantage Risk Management Co Ltd | 0.22 | 0.29 | 0.26 |
CARE.JK | PT Metro Healthcare Indonesia Tbk | 0.12 | 0.54 | 0.5 |
HEAL.JK | Medikaloka Hermina Tbk PT | 0.14 | 0.69 | 0.64 |
MIKA.JK | Mitra Keluarga Karyasehat Tbk PT | 0 | 0.42 | 0.42 |
PSQ.AX | Pacific Smiles Group Ltd | 0.27 | 0.15 | 0.13 |
RPH.BK | Ratchaphruek Hospital PCL | 0 | 0.2 | 0.2 |
SILO.JK | Siloam International Hospitals Tbk PT | 0.09 | 0.52 | 0.5 |
SRAJ.JK | Sejahteraraya Anugrahjaya Tbk PT | 0.03 | -0.78 | -0.77 |
Low | High | |
Unlevered beta | 0.24 | 0.45 |
Relevered beta | 0.27 | 0.51 |
Adjusted relevered beta | 0.51 | 0.67 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for SAME.JK:
cost_of_equity (12.10%) = risk_free_rate (6.85%) + equity_risk_premium (8.40%) * adjusted_beta (0.51) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.